title: [The efficacy of degarelix on LUTS (Lower urinary tract symptoms) relief in patients with prostate cancer].
abstract: Hormonal therapy is one of the treatment options for prostate cancer patients. There are many hormonal treatments modality to block the testosterone effect on prostate cancer cell proliferation. Degarelix is an innovative molecule able to antagonize the GnRH receptor with comparable oncological results to GnRH agonist, but with less side effects, avoiding the flare up phase, and better efficacy in LUTS relief. These characteristics of degarelix can impact on the clinical decision making to choose a therapy instead of another.
authors.affiliation: Department of Urology, Alma Mater Studiorum University of Bologna, Sant'Orsola-Malpighi Hospital, Italy. alessandro.bertaccini@gmail.com
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bertaccini
authors.forename: Debora
authors.initials: D
authors.lastname: Marchiori
mesh_terms: D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000150:complications*
chemical_list: D009842:Oligopeptides; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D007987:Gonadotropin-Releasing Hormone